NCT06722742

Brief Summary

\*Ketamine:\* Ketamine is a medication that can help reduce shivering by blocking certain nerve signals in the brain. It's like a "nerve blocker" that helps calm down the body's shivering response. \- \*Tramadol:\* Tramadol is a pain medication that can also help reduce shivering. It works by affecting the brain's temperature regulation centers, which helps to reduce the shivering response.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
250

participants targeted

Target at P50-P75 for phase_3

Timeline
Completed

Started Sep 2024

Shorter than P25 for phase_3

Geographic Reach
1 country

3 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 30, 2024

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

November 28, 2024

Completed
11 days until next milestone

First Posted

Study publicly available on registry

December 9, 2024

Completed
21 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 30, 2024

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

January 30, 2025

Completed
Last Updated

December 9, 2024

Status Verified

December 1, 2024

Enrollment Period

3 months

First QC Date

November 28, 2024

Last Update Submit

December 3, 2024

Conditions

Keywords

shiveringSpinal anesthesiaKetamineTramadol and Metclopromide

Outcome Measures

Primary Outcomes (1)

  • Shivering

    Scale validated by crossley and mahajan Grade 0: No shivering Grade 1: Piloerection, peripheral vasoconstriction, peripheral cyanosis, or mild fasciculation of the face or neck, but no visible muscle activity Grade 2: Visible muscle activity in one muscle group Grade 3: Visible muscle activity in more than one muscle group Grade 4: Gross muscle activity involving the entire body

    20 minutes to 12 hours

Study Arms (2)

Group K

ACTIVE COMPARATOR

Group K receive Inj: ketamine

Drug: Ketamine only

Group T

ACTIVE COMPARATOR

Group T receive Inj: Tramadol

Drug: Tramadol

Interventions

Inj: Ketamine given to group K following spinal anesthesia

Group K

Inj Tramadol given to group T following spinal anesthesia

Group T

Eligibility Criteria

Age18 Years - 40 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Pateint for elective cesarean section
  • Age 18 to 40 years
  • ASA 1 and 2

You may not qualify if:

  • ASA 2 and 3
  • Cesarean section requiring general anesthesia
  • Hypersensitivity to Ketamine, Tramadol and Opiods
  • History of cardiovascular disease

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (3)

Liaquat National Hospital and Medical College

Karachi, Sindh, 75500, Pakistan

RECRUITING

Liaquat National Hospital and Medical College

Karachi, Sindh, Pakistan

RECRUITING

Liaquat National Hospital and Medical College

Karachi, Sindh, Pakistan

RECRUITING

Related Links

MeSH Terms

Interventions

Tramadol

Intervention Hierarchy (Ancestors)

CyclohexanolsHexanolsFatty AlcoholsAlcoholsOrganic ChemicalsDimethylaminesMethylaminesAminesLipids

Study Officials

  • Nazish Dr Nazish Kanwal

    Liaquat national hospital and medical college

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Nazish Dr Nazish Kanwal

CONTACT

Shazor khan Khattak

CONTACT

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

November 28, 2024

First Posted

December 9, 2024

Study Start

September 30, 2024

Primary Completion

December 30, 2024

Study Completion

January 30, 2025

Last Updated

December 9, 2024

Record last verified: 2024-12

Data Sharing

IPD Sharing
Will not share

Patient confidentiality\*: Sharing IPD could compromise patient confidentiality and anonymity, potentially harming participants or their families. * Informed consent\*: Participants may not have provided informed consent for their data to be shared, which could raise ethical concerns.

Locations